These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 11241268)

  • 1. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
    Ueda J; Iwata T; Ono M; Takahashi M
    Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
    Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
    Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
    Saleh HA; El-Fakharany M; Makki H; Kadhim A; Masood S
    Diagn Cytopathol; 2009 May; 37(5):324-32. PubMed ID: 19191294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY; Li GD; Liu HB; Jiang LL
    Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.
    Frisman DM; McCarthy WF; Schleiff P; Buckner SB; Nocito JD; O'Leary TJ
    Mod Pathol; 1993 Mar; 6(2):179-84. PubMed ID: 8483888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of HBME-1 immunostaining in serous effusions.
    Ascoli V; Carnovale-Scalzo C; Taccogna S; Nardi F
    Cytopathology; 1997 Oct; 8(5):328-35. PubMed ID: 9313985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
    Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
    Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
    Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
    Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.
    Kitazume H; Kitamura K; Mukai K; Inayama Y; Kawano N; Nakamura N; Sano J; Mitsui K; Yoshida S; Nakatani Y
    Cancer; 2000 Feb; 90(1):55-60. PubMed ID: 10692217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic value of thrombomodulin immunolocalization in serous effusions.
    Ascoli V; Scalzo CC; Taccogna S; Nardi F
    Arch Pathol Lab Med; 1995 Dec; 119(12):1136-40. PubMed ID: 7503662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
    De Angelis M; Buley ID; Heryet A; Gray W
    Cytopathology; 1992; 3(2):111-7. PubMed ID: 1617160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
    Delahaye M; van der Ham F; van der Kwast TH
    Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the monoclonal antibody MOC-31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology.
    Kundu UR; Krishnamurthy S
    Cancer Cytopathol; 2011 Aug; 119(4):272-8. PubMed ID: 21732548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant.
    Aerts JG; Delahaye M; van der Kwast TH; Davidson B; Hoogsteden HC; van Meerbeeck JP
    Diagn Cytopathol; 2006 Aug; 34(8):523-7. PubMed ID: 16850492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.